Rafael Holdings Q4 net loss narrows on lower costs
Overview
US biotechnology firm's fiscal Q4 net loss narrowed year over year on lower administrative expenses
Fiscal Q4 revenue declined year over year
Quarterly research and development expenses were flat year over year
Outlook
Company has requested a rare pediatric disease priority review voucher with NDA submission
Result Drivers
ADMINISTRATIVE COSTS - Co said lower payroll, stock-based compensation and professional fees reduced administrative expenses
SETTLEMENT GAINS - Co cited gains from settlements of accounts payable and convertible notes payable as a factor in reduced annual net loss
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Loss attributab e to company | $9.20 mln | ||
Q4 Operating Income | -$9.73 mln |
Reuters Recommended Reads
Oct 28 - Viking Therapeutics posts bigger-than-expected Q3 loss as costs rise
Oct 27 - Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidance
Oct 29 - Ligand Pharmaceuticals Q3 royalty revenue jumps 51%
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)